about
Transforming growth factor beta2 is a neuronal death-inducing ligand for amyloid-beta precursor proteinGlycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeuticsStructural changes of region 1-16 of the Alzheimer disease amyloid beta-peptide upon zinc binding and in vitro aging.Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon.Vaccines: past, present and future.Midkine as a factor to counteract the deposition of amyloid β-peptide plaques: in vitro analysis and examination in knockout mice.Epitope structure and binding affinity of single chain llama anti-β-amyloid antibodies revealed by proteolytic excision affinity-mass spectrometry.Transgenic tomatoes expressing human beta-amyloid for use as a vaccine against Alzheimer's disease.The inflammatory response in Alzheimer's disease.Lipid-induced beta-amyloid peptide assemblage fragmentationAbeta DNA vaccination for Alzheimer's disease: focus on disease prevention.The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease.Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysisVaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhagesTherapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosisCombined treatment of Aβ immunization with statin in a mouse model of Alzheimer's disease.Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's diseaseAttenuation of beta-amyloid-induced toxicity by sialic-acid-conjugated dendrimers: role of sialic acid attachment.The immune system, amyloid-beta peptide, and Alzheimer's disease.The expanding role of BDNF: a therapeutic target for Alzheimer's disease?Ageing and neuronal vulnerability.Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeuticsRecent developments in mucosal vaccines against prion diseases.Current experimental therapy for Alzheimer's diseaseNasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease.Tg-SwDI transgenic mice exhibit novel alterations in AbetaPP processing, Abeta degradation, and resilient amyloid angiopathy.The relationship between Helicobacter pylori infection and Alzheimer's disease in Japan.Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions.Alzheimer's and non-alzheimer's dementia: a critical review of pharmacological and nonpharmacological strategies.Glycosylation profiles of epitope-specific anti-beta-amyloid antibodies revealed by liquid chromatography-mass spectrometry.The coming of age of virus-like particle vaccines.Imaging microglial activation during neuroinflammation and Alzheimer's disease.Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial.Immunodrugs: breaking B- but not T-cell tolerance with therapeutic anticytokine vaccines.Microglia: key innate immune cells of the brain.Successes and failures for drugs in late-stage development for Alzheimer's diseasePotential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches.Perspectives on Inhibiting β-Amyloid Aggregation through Structure-Based Drug Design.Abl deregulates Cdk5 kinase activity and subcellular localization in Drosophila neurodegeneration.Transgenic potato expressing Abeta reduce Abeta burden in Alzheimer's disease mouse model.
P2860
Q24338342-56A090BB-6198-4F64-BE2B-6428A7C9DEE1Q24685475-3B3F19B8-6F9C-4EC4-9940-3E7360627C37Q33227600-2636CAB7-4B6E-45DD-8B26-DF380AC10D54Q33289262-87CF52F8-ACE3-4ABC-97B0-D4E86109C16CQ34409178-87181154-E8EB-4422-BE7A-05661BAA2832Q34506576-63E19032-83B5-4CC4-83C1-E726658E6E22Q34529106-F8F1E0FD-C759-4D07-9DA9-9A3EBCCB3755Q34792832-662B7894-3D1C-4B53-BC34-5C4D5CEC2BABQ34803247-68F0F249-546C-48EE-9687-9934E66086DBQ35128933-76E8F3E5-FD6D-48AE-B20D-71390AC73FA0Q35156471-4DEE8369-DE35-42CE-950C-7F88AD68093BQ35183183-C8BEEBBC-7FA1-4796-B32A-51727597E554Q35222076-27237F1C-123E-4FCC-B237-4145304D4AFFQ35606537-B5B124E9-CE5F-442F-BFC5-745F532F3BCCQ35623240-D34A0136-D151-43EC-9930-791A21BCB8B7Q35818921-3FDF6B2B-1EB0-4FEA-A347-B770E40D68C1Q36026890-6ECF2EE8-54E0-453C-AC06-7FF6CE8B5033Q36074464-25C0F38B-DE55-4CD1-94CD-EE5B801F68E0Q36121068-E5B67447-2E9B-42FB-A5EE-F9824A44EFC8Q36325596-BA171CEC-5822-4AB8-8AFE-DEE166C5FC35Q36428039-8B8B5DB9-BB49-4AB7-A7B9-1533CD3865E7Q36626374-88AA54F7-E348-483B-A466-47560567C0EBQ36728797-D8B8389D-FD10-44CB-83DF-0D76C9542E73Q36731881-CA1AC84B-5B6C-4319-ACBA-1FBB7B3F8D68Q36746854-5F051919-4964-4FBC-885C-8B7178F14FCBQ36778265-A5FD0BBE-A974-421E-8580-208EFEF67B1CQ37091521-56BA40EB-B357-4AD6-9155-798041F82FA1Q37101754-6CD61A27-E7E9-4D48-97AD-BAAD22231507Q37106942-44627DCC-87B4-4C87-9FF7-B5594B92D302Q37287652-0A172A08-138B-4F02-8C7C-6A5102E1CEDCQ37309265-C364FE53-0726-4773-B018-CE5395EBF51CQ37340359-DD038FCF-6191-4D21-8F64-F0D81BEF4B4FQ37342565-FDE08F55-E6B2-4216-9A61-8BA407F693BCQ37773295-054DA506-916C-4FE6-AFAB-2DA2C53255C1Q37809665-8A12CC02-A968-465E-B136-22DF395491C1Q38128773-52478E6B-8D3B-448F-96FB-08EFF66881C4Q38169212-3F7B8AFD-C5C4-4991-94F5-B24E15ECA564Q38558352-52AB1976-553E-4FCA-A281-563DE38D7BC2Q40239614-5E04953F-B456-44ED-929E-0D41D6510448Q40347090-26A30AF4-A660-4C66-BFB7-9F8B1361B811
P2860
description
article published in the Proce ...... f the United States of America
@en
article publié dans les Procee ...... f the United States of America
@fr
im Oktober 2004 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2004
@uk
name
Immunotherapy for Alzheimer's disease
@en
Immunotherapy for Alzheimer's disease
@nl
type
label
Immunotherapy for Alzheimer's disease
@en
Immunotherapy for Alzheimer's disease
@nl
prefLabel
Immunotherapy for Alzheimer's disease
@en
Immunotherapy for Alzheimer's disease
@nl
P2093
P2860
P356
P1476
Immunotherapy for Alzheimer's disease
@en
P2093
Daniela Fenili
David S Gelinas
Joanne McLaurin
Kevin DaSilva
P2860
P304
P356
10.1073/PNAS.0404866101
P407
P433
Supplement 2
P478
101 Suppl 2
P577
2004-10-05T00:00:00Z